These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
225 related items for PubMed ID: 28433478
1. Investigation on acute effects of enzyme replacement therapy and influence of clinical severity on physiological variables related to exercise tolerance in patients with late onset Pompe disease. Sechi A, Salvadego D, Da Ponte A, Bertin N, Dardis A, Cattarossi S, Devigili G, Reccardini F, Bembi B, Grassi B. Neuromuscul Disord; 2017 Jun; 27(6):542-549. PubMed ID: 28433478 [Abstract] [Full Text] [Related]
4. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group. Filosto M, Cotti Piccinelli S, Ravaglia S, Servidei S, Moggio M, Musumeci O, Donati MA, Pegoraro E, Di Muzio A, Maggi L, Tonin P, Marrosu G, Sancricca C, Lerario A, Sacchini M, Semplicini C, Bozzoni V, Telese R, Bonanno S, Piras R, Maioli MA, Ricci G, Vercelli L, Galvagni A, Gallo Cassarino S, Caria F, Mongini T, Siciliano G, Padovani A, Toscano A. Adv Ther; 2019 May; 36(5):1177-1189. PubMed ID: 30879255 [Abstract] [Full Text] [Related]
7. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. Montagnese F, Barca E, Musumeci O, Mondello S, Migliorato A, Ciranni A, Rodolico C, De Filippi P, Danesino C, Toscano A. J Neurol; 2015 May; 262(4):968-78. PubMed ID: 25673129 [Abstract] [Full Text] [Related]
8. The emerging phenotype of late-onset Pompe disease: A systematic literature review. Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, Case LE, Jones HN, Kishnani PS. Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884 [Abstract] [Full Text] [Related]
9. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E, Crescimanno G, Tonin P, Parini R, Morandi L, Marrosu G, Greco G, Musumeci O, Di Iorio G, Siciliano G, Donati MA, Carubbi F, Ermani M, Mongini T, Toscano A, Italian GSDII Group. J Neurol; 2012 May; 259(5):952-8. PubMed ID: 22081099 [Abstract] [Full Text] [Related]
11. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry. Scheidegger O, Leupold D, Sauter R, Findling O, Rösler KM, Hundsberger T. J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608 [Abstract] [Full Text] [Related]
16. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. Stockton DW, Kishnani P, van der Ploeg A, Llerena J, Boentert M, Roberts M, Byrne BJ, Araujo R, Maruti SS, Thibault N, Verhulst K, Berger KI. J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257 [Abstract] [Full Text] [Related]